| 3QPN: reference: Use of Structure-Based Design to Discover a Potent, Selective, In Vivo Active Phosphodiesterase 10A Inhibitor Lead Series for the Treatment of Schizophrenia., Helal CJ, Kang Z, Hou X, Pandit J, Chappie TA, Humphrey JM, Marr ES, Fennell KF, Chenard LK, Fox C, Schmidt CJ, Williams RD, Chapin DS, Siuciak J, Lebel L, Menniti F, Cianfrogna J, Fonseca KR, Nelson FR, O'Connor R, Macdougall M, McDowell L, Liras S, J Med Chem. 2011 Jun 8. PMID: 21650160 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).